Home > Insider Trading > Filing (0000950170-24-064598)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1563880	Trevi Therapeutics Inc.	TRVI	Pharmaceutical Preparations (2834)	450834299

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873253	Lisa Delfini	C/O Trevi Therapeutics, Inc. 195 Church Street, 16Th Floor New Haven CT 06510	Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-22	16,043	$0.51	57,629	No	4	M	Direct
Common Stock	Disposition	2024-05-22	4,350	$2.64	53,279	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-05-22	16,043	$0.00	16,043	$0.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
48,125		2032-02-10	No	4	M	Direct

Footnotes

Includes 5,685 shares purchased through the Issuer's employee stock purchase plan.
This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on May 22, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.